Oct 9 2009
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award is a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses.
"I share this award with our co-founder Dr. Martin Gleave and all of our employees at OncoGenex, whose contributions and exceptional dedication to our programs have led to a series of major clinical and business advancements over the past 12 months," said Scott Cormack, President and CEO of OncoGenex.
"Over the past year, we have presented impressive data from the clinical trials of our lead drug candidate, OGX-011, for the treatment of advanced prostate cancer; reached agreements with the FDA on the design of two Phase 3 trials for evaluating OGX-011 treatment in advanced prostate cancer via the FDA's special protocol assessment process; received Fast Track designations from FDA for OGX-011 in combination with both first-line and second-line chemotherapy in advanced prostate cancer, which are expected to streamline the regulatory review process; presented data from our Phase 1 clinical trial evaluating our second product candidate, OGX-427; and initiated another clinical trial with OGX-427 in bladder cancer," Cormack said.
"For the remaining 2009 year, we are committed to securing a partner to support the final stage of development of OGX-011 and announcing additional development initiatives for our other product candidates."
Ernst & Young's Entrepreneur Of The Year(R) Award encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. The Ernst & Young Entrepreneur Of The Year(R) award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries. Award winners were selected by an independent judging panel made up of regional business, academic and community leaders.
Source:
OncoGenex Pharmaceuticals, Inc.